## **What is ferric carboxymaltose injection?**
HCPCS J1439 is the code for ferric carboxymaltose (Injectafer®), billed per 1 mg when administered as an intravenous iron product for adults. Injectafer treats iron deficiency and iron deficiency anemia (IDA) when oral iron is not tolerated or has an unsatisfactory response. It is also indicated for certain patients with non–dialysis–dependent chronic kidney disease (NDD-CKD) and other approved/compendia-supported indications.
The drug is given by IV infusion in clinic or hospital settings using dosing regimens that may include two doses separated by at least 7 days or a single larger dose, depending on weight and indication; total cumulative dose limits apply, and retreatment is allowed if iron deficiency anemia reoccurs (N. C. Medicaid, 2018).
Key points providers should know at a glance:
- Billed per 1 mg (one HCPCS unit = 1 mg).
- Indications include iron deficiency anemia (intolerance or unsatisfactory response to oral iron) and NDD-CKD; other uses (e.g., chemotherapy-induced anemia, heart-failure related iron deficiency) are covered when local policy/compendia support them.
- Requires complete and accurate documentation (labs such as serum ferritin and transferrin saturation/TSAT, diagnosis codes, prior oral-iron trial or intolerance) to support medical necessity and reimbursement.
- NDC reporting and correct NDC units are commonly required by payers (check your state Medicaid or MAC rules).
## **Documentation requirements**
When billing HCPCS code J1439 for ferric carboxymaltose injection, providers must supply complete and accurate documentation to support medical necessity. This includes:
- **Diagnosis confirmation**: Clinical evidence must confirm iron deficiency through labs (e.g., serum ferritin, transferrin saturation/TSAT). Both absolute iron deficiency and functional iron deficiency are eligible indications when properly documented.
- **Treatment history**: Records should note an unsatisfactory response to oral iron therapy or intolerance, as well as whether the patient requires supplemental iron to maintain iron balance.
- **Underlying conditions**: Documentation must reflect the chronic disease causing the anemia (e.g., chronic kidney disease, heart failure, or other chronic diseases classified under compendia support).
- **Clinical outcomes**: Progress notes should track changes in exercise capacity, symptoms, and hemoglobin levels to justify continued or repeat courses.
- **Drug and administration details**: Include the total dose administered (per mg), the date, route (intravenous iron therapy), and NDC reporting if required.
- **Modifiers**: Apply JW/JZ modifiers as dictated by CMS when vials are used to account for drug waste.
## **Billing requirements**
Proper reimbursement for HCPCS Code J1439 requires attention to detailed billing rules, especially since it represents ferric carboxymaltose 1 mg and differs from other intravenous iron therapies.
- **Units billed**: Report J1439 per 1 mg of drug administered. For example, a 750 mg infusion should be billed as 750 units.
- **Drug identifiers**: Include the appropriate National Drug Code (NDC) on the claim form to align with payer requirements and avoid denials.
- **Comparative agents**: J1439 is specific to ferric carboxymaltose and should not be confused with other intravenous iron products such as sodium ferric gluconate complex or iron sucrose. Each has its own HCPCS code and billing guidelines.
- **Eligibility**: Medicare and commercial payers cover J1439 when medical necessity is established. Note that coverage excludes iron deficiency anemia without documented underlying causes (e.g., chronic kidney disease, heart failure, chemotherapy-induced anemia).
- **Documentation**: Both the patient and healthcare provider records must include the dose, route (IV infusion), and date of service. Claims may be denied if incomplete or inconsistent.
- **Modifiers**: Use JW (drug waste) or JZ (no waste) modifiers as required by CMS when billing for single-use vials.
## **Other relevant codes**
- J1756 – Injection, iron sucrose, 1 mg
- J2916 – Injection, sodium ferric gluconate complex, 12.5 mg
- J1437 – Injection, ferric derisomaltose (Monoferric), 10 mg
### **References**
N. C. Medicaid (2018, February 5). Ferric carboxymaltose (Injectafer) HCPCS code J1439: Billing guidelines. https://medicaid.ncdhhs.gov/blog/2018/02/05/ferric-carboxymaltose-injectafer-hcpcs-code-j1439-billing-guidelines
Frequently asked questions
